Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELB245 in Incontinent Overactive Bladder
NCT00439192Phase 2Terminated
- Sponsor
- elbion
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ELB-245 in overactive bladder (OAB) and urinary incontinence (UI), sponsored by elbion. Primary endpoint: mean number of micturitions. Started Feb 2007; status: terminated.
02
Drugs
ELB-245
03
Conditions
overactive bladder (OAB)urinary incontinence (UI)
Beyond the preview
Go deeper on NCT00439192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00439192.